The bill
To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.
HR. 6130, 119th Congress — read as touching Medical Devices.
To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.
Bill ID: 119/hr/6130
Last Updated: November 19, 2025
Sponsored by
Rep. Buchanan, Vern [R-FL-16]
ID: B001260
Follow the money
The sponsor
Rep. Buchanan, Vern [R-FL-16]
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
$66,000 raised
20 itemised contributions to this sponsor, pulled from FEC filings.
Bill's Journey to Becoming a Law
Track this bill's progress through the legislative process
Latest Action
Invalid Date
Introduced
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
🏛️
Committee Review
🗳️
Floor Action
✅
Passed Senate
🏛️
House Review
🎉
Passed Congress
🖊️
Presidential Action
⚖️
Became Law
📚 How does a bill become a law?
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Bill Summary
No summary available
💰 Campaign Finance Network
Rep. Buchanan, Vern [R-FL-16]
Congress 119 • 2024 Election Cycle
Total Contributions
$66,000
15 donors
PACs
$0
Organizations
$0
Committees
$0
Individuals
$66,000
No PAC contributions found
No organization contributions found
No committee contributions found
1
GARCIA, MARIO
$6,600
2
GARCIA, IVIS
$6,600
3
COPELAND, GERRET
$6,600
4
ARISON, MICKY
$6,600
5
ARISON, MADELEINE
$6,600
6
RICHARDS, CHRISTINE
$3,300
7
RICHARDS, DANIEL
$3,300
8
BENJAMIN, STEPHEN
$3,300
9
JOHNSON, TRAVIS
$3,300
10
COPELAND, KYM
$3,300
11
MURRAY, R. CHARLES
$3,300
12
MCGILLICUDDY, DENNIS
$3,300
13
MCGILLICUDDY, GRACI
$3,300
14
ELLER, SCOTT
$3,300
15
RYAN, JOSEPH H
$3,300
Donor Network - Rep. Buchanan, Vern [R-FL-16]
PACs
Organizations
Individuals
Politicians
Hub layout: Politicians in center, donors arranged by type in rings around them.
Loading...
Showing 27 nodes and 20 connections (34 secondary connections hidden)
Total contributions: $66,000
Top Donors - Rep. Buchanan, Vern [R-FL-16]
Showing top 15 donors by contribution amount
15 Individuals
Industry Impact
Which industries are materially affected by specific provisions in this bill. 3 helped.
- +Medical Devicesconfidence 0.90
Section 2(a)(2) adds coverage for Alzheimer's disease and related dementias early detection screening tests, which include genomic sequencing blood tests, single-analyte tests, multiplex panel tests, whole genome sequencing, protein expression, etc. These are medical devices that would be reimbursed by Medicare, creating a market expansion for manufacturers of such diagnostic tests.
- +Biotech & Researchconfidence 0.85
Section 2(a)(2) defines covered tests to include genomic sequencing, whole exome, whole transcriptome, and protein expression analyses, which are biotechnology-based diagnostic tests. Medicare coverage would increase demand for biotech firms developing and manufacturing these screening tests.
- +Hospitals & Health Systemsconfidence 0.80
Section 2(b) amends payment provisions to include Alzheimer's disease and related dementias early detection screening tests under Section 1833(h)(1)(A). Hospitals and health systems that administer these tests would receive Medicare reimbursement, increasing revenue.